Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of assisted versus self-administered subcutaneous trastuzumab in operable HER2-positive early breast cancer
NL-OMON43630Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of trastuzumab in breast cancer (2 cohorts), sponsored by Roche. Primary endpoints: Clinical adverse events, Serious adverse events and 2 more. Started Sep 2012; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON43630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43630.